A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B

Author(s):

Man Fung Yuen, Chi Yi Chen, Chun Jen Liu, Wen Juei Jeng, Magdy Elkhashab, Carla S. Coffin, Won Kim, Susan Greenbloom, Alnoor Ramji, Young S. Lim, Yoon J. Kim, Scott K. Fung, Dong J. Kim, Jeong Won Jang, Kwan Sik Lee, Radhakrishnan P. Iyer, Chelsea Macfarlane, Kathy Jackson, Stephen A. Locarnini, Henry L.Y. Chan, Nezam H. Afdhal

Details:

Liver International, Volume 43, Issue 1, 2023-01-01

Article Link: Click here

Affiliations:

• University of Toronto
• Beth Israel Deaconess Medical Center
• Seoul National University College of Medicine
• National Taiwan University Hospital
• Chang Gung University
• University of Ulsan College of Medicine
• Cumming School of Medicine
• Royal Melbourne Hospital
• Prince of Wales Hospital Hong Kong
• Toronto General Hospital
• The Catholic University of Korea Seoul St. Mary's Hospital
• Hallym University, College of Medicine
• Gangnam Severance Hospital
• Chiayi Christian Hospital
• The University of Hong Kong, State Key Laboratory of Liver Research
• Gastrointestinal Research Institute
• Toronto Digestive Disease Associates
• Spring Bank Pharmaceuticals